focus -WSS

focus

author：fashion 2025-09-28 01:31:45 - browse：2639

Neumora, a privately held biotech company, is moving into the final phase of testing with a novel treatment for depression that showed promise in a mid-stage trial.

The drug, a daily pill called navacaprant, led to statistically significant improvements over placebo on a measurement of disease severity for patients with moderate to severe major depressive disorder, Neumora said Tuesday. In the eight-week study, the medicine also led to improvements in patient-reported anhedonia, a reduced ability to experience pleasure that often accompanies severe depression.

Navacaprant’s statistically significant benefits came from a pre-specified subset of 100 patients in a study that enrolled 171 people. In the total population, including 71 patients who had mild to moderate disease, navacaprant’s effect on depressive symptoms was numerically superior to placebo but did not reach the threshold of statistical significance, missing the study’s primary endpoint.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Norman Reedus' Daryl Dixon

knowledge

WSS

AdventHealth escalates lawsuit against insurance vendor Multiplan

A single drug, study failures leave Anavex with nothing but cash

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Ahead of JPM, here's who's profiting most in health care

'Reaching a detente': STAT's Helen Branswell on covering Covid

explore

focus

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Stanford updates investigation of president’s past research

Drug repurposing or repositioning? The language matters

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

What does generative AI mean for health care? We asked experts

Why the Crimean Bridge is key to Russia's war in Ukraine

Moonlake's readout produced a cash windfall. Risks remain

India sets sights on home

Psychedelics group wrestles with new pharma identity

Researchers separate signal from noise in heart wearable data

focus

UCB departs biotech trade group BIO

Why the Crimean Bridge is key to Russia's war in Ukraine

Man who had jail sentence commuted by Trump arrested again

Man who had jail sentence commuted by Trump arrested again

Actors' union, Hollywood studios squabble over which side to blame as strike enters 5th day

How a scoliosis diagnosis changed the life of one young dancer

hotspot

knowledge

Wikipedia

Wikipedia